This study is designed to evaluate the safety and efficacy of cord blood-derived CAR-NK019 in the treatment of refractory/relapsed central nervous system lymphoma.

This study is a single-center, open, single-arm incremental, exploratory study designed to evaluate the safety and efficacy of cord blood-derived CAR-NK019 in the treatment of refractory/relapsed central nervous system lymphoma.

The study will be divided into two stages: Phase I is the dose escalation study, which is strictly based on the "3+3" dose escalation principle, and three dose groups are set up, which are administered through the ommaya capsule ventricle, and each dose is infused once a week for 3 weeks. Three to six subjects are intended to be enrolled in each dose group, with each subject observed for at least 28 days after receiving the initial infusion and a long-term follow-up period of two years after each infusion. Phase II is the dose expansion phase: The recommended dose and administration mode for this phase will be determined after comprehensive consideration based on safety data obtained in phase I, the proliferation and survival of CAR-NK cells in vivo, and clinical efficacy data, and 24 effective subjects will be recruited for further evaluation of efficacy and safety. Long-term follow-up lasted up to 2 years after the first CAR-NK transfusion in each patient.

Inclusion Criteria:

• Patients with refractory/recurrent CNS lymphoma must meet all of the following criteria to be eligible:

  1. Voluntarily participate in the study and sign the informed consent;

  2. Age 18-75 years old, male or female;

  3. Diffuse large B-cell lymphoma (DLBCL) was confirmed by histology. CD19 expression was positive by lymphoma pathology or flow cytometry, and CD19 expression was ≥20% by IHC.

  4. Imaging showed no evidence of systemic lymphoma;

  5. Meets any of the following definitions for refractory/relapsed CNS lymphoma: no complete response has been achieved with prior 2-line regimen including methotrexate or cytarabine-based regimen; Disease progression during any treatment; The stable time of disease after effective treatment is less than 6 months; Disease progression or recurrence within 12 months after autologous hematopoietic stem cell transplantation.

  6. Imaging showed the presence of at least one measurable lesion, with a minimum diameter of ≥10mm;

  7. Expected survival ≥3 months;

  8. ECOG score 0-3 points;

  9. Adequate organ function reserve:

     • alanine aminotransferase, ASpartate aminotransferase ≤ 2.5× UNL (upper limit of normal);
     • Creatinine clearance (Cockcroft-Gault method) ≥60 mL/min;
     • Serum total bilirubin and alkaline phosphatase ≤1.5× UNL;
     • Glomerular filtration rate >50ml/min
     • cardiac ejection fraction (EF) ≥45%;
     • Basic oxygen saturation >92% in indoor natural air environment;
     • Blood routine: absolute number of neutrophils >×109/L, platelet count 45×109/L, hemoglobin 80g/L;

  10. Previous autologous hematopoietic stem cell transplantation is allowed, and the interval between stem cell transfusion and CAR-NK transfusion is ≥3 months;

  11. Previous CAR-T cell therapy is allowed, and the time interval between CAR-T transfusion and CAR-NK transfusion is ≥3 months;

  12. Female subjects of childbearing age must test negative for pregnancy and agree to use effective contraception during the test;

  13. Approved anti-tumor therapies, such as systemic chemotherapy, whole body radiotherapy and immunotherapy, have been discontinued for at least 3 weeks before the study; Discontinuation of targeted drug regiments without chemotherapy for at least 2 weeks;

Exclusion Criteria:

• Subjects who meet any of the following criteria will not be admitted to the study:

  1. Allergic to any of the components of cell products;
  2. History of other tumors;
  3. Acute grade II-IV (Glucksberg standard) GvHD or generalized chronic GvHD occurred after previous allogeneic hematopoietic stem cell transplantation; Or are receiving anti-GVHD treatment;
  4. Have received gene therapy within the past 3 months;
  5. Active infections requiring treatment (except simple urinary tract infections, bacterial pharyngitis), but prophylactic antibiotic, antiviral and antifungal infection treatment is permitted;
  6. Persons infected with hepatitis B (HBsAg positive, but HBV-DNA<103 is not excluded) or hepatitis C virus (including virus carriers), syphilis and other acquired and congenital immunodeficiency diseases, including but not limited to HIV-infected persons;
  7. Subjects with Grade III or IV cardiac dysfunction according to the New York Heart Association's cardiac function grading criteria;
  8. Patients who received antitumor therapy in the early stage but did not recover toxicity (CTCAE 5.0 toxicity did not recover to ≤ grade 1, except fatigue, anorexia, alopecia);
  9. Previous history of epilepsy, autoimmune encephalitis, cerebral infarction or cerebral hemorrhage within 6 months;
  10. Whole-body enhanced CT or PET/CT suggests evidence of systemic lymphoma;
  11. Lactating women who are unwilling to stop breastfeeding;
  12. Any other circumstances that the investigator believes may increase the risk to the subject or interfere with the test results;
  13. Patients requiring more than 10mg of dexamethasone per day for 3 days prior to enrollment;
  14. Patients who cannot tolerate ommaya capsule implantation;
  15. Those who cannot tolerate enhanced magnetic resonance imaging.